Table I.
Demographic and clinical characteristics for study populations.
| Variable | LUAD N=280 | LUSC N=287 | P-value |
|---|---|---|---|
| Age, median years (interquartile range) | 67.00 (13.25) | 69.00 (11.00) | 0.01a |
| Sex, n (%) | 3.77×10−10 | ||
| Female | 146 (52.14) | 75 (26.13) | |
| Male | 134 (47.86) | 212 (73.87) | |
| Ethnicity, n (%) | 0.01 | ||
| Asian | 2 (0.71) | 3 (1.05) | |
| Black or African American | 29 (10.36) | 19 (6.62) | |
| White | 226 (80.71) | 218 (75.96) | |
| Unknown | 23 (8.21) | 47 (16.38) | |
| Pack-years smoked, median (interquartile range) | 36.50 (30.00) | 50.00 (33.87) | 3.02×10−8a |
| Survival time, median months (interquartile range) | 216.00 (69.00) | 244.00 (975.00) | 0.37a |
| Dead, n (%) | 68 (24.29) | 87 (30.31) | 0.13 |
| History of other malignancy, n (%) | 0.08 | ||
| No | 227 (81.07) | 249 (86.76) | |
| Yes | 53 (18.93) | 38 (13.24) | |
| Kras gene analysis indicator, n (%) | 9.27×10−7 | ||
| No | 149 (53.21) | 205 (71.43) | |
| Yes | 38 (13.57) | 10 (3.48) | |
| Unknown | 93 (33.21) | 72 (25.09) | |
| EGFR mutation status, n (%) | 1.38×10−7 | ||
| No | 124 (44.29) | 186 (64.81) | |
| Yes | 49 (17.5) | 16 (5.57) | |
| Unknown | 107 (38.21) | 85 (29.62) |
a
P<0.05, Wilcoxon rank-sum test. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; EGFR, epithelial growth factor receptor.